Table 2. Shows the AUC, sensitivity, and specificity, of each ROC-analysis and percentage of cases correctly identified, and combination of biomarkers.
| AUC (CI) | P values | Sens. % | Spec. % | PPV. % | NPV. % | DA % | |
|---|---|---|---|---|---|---|---|
| Biomarkers: UC (n = 60) vs. CD (n = 72) | |||||||
| BGM | 0.95 (0.90–0.98) | <0.001 | 93 | 87 | 86 | 94 | 90 |
| EL-NE | 0.85 (0.78–0.91) | <0.001 | 78 | 78 | 74 | 81 | 75 |
| C5M | 0.61 (0.52–0.69) | <0.05 | 48 | 76 | 63 | 64 | 55 |
| Pro-C5 | 0.65 (0.56–0.73) | <0.01 | 85 | 43 | 55 | 78 | 60 |
| VICM, see Mortensen et al. [14] | |||||||
| CRP | 0.56 (0.47–0.65) | NS | 100 | 39 | 56 | 100 | 54 |
| BGM + VICM* | 0.98 (0.93–1.00) | <0.001 | 94 | 96 | 94 | 96 | 94 |
| Biomarkers: UC (n = 60) vs. Colonic CD (n = 48) | |||||||
| BGM | 0.94 (0.88–0.98) | <0.001 | 83 | 95 | 93 | 88 | 88 |
| EL-NE | 0.87 (0.79–0.93) | <0.001 | 60 | 93 | 88 | 74 | 87 |
| C5M | 0.62 (0.53–0.72) | NS | 79 | 52 | 57 | 76 | 52 |
| Pro-C5 | 0.69 (0.59–0.78) | <0.01 | 79 | 48 | 55 | 74 | 69 |
| VICM, see Mortensen et al. [14] | |||||||
| CRP | 0.52 (0.39–0.69) | NS | 45 | 54 | 43 | 60 | 53 |
| BGM+VICM* | 0.97 (0.92–1.0) | <0.001 | 96 | 91 | 90 | 96 | 94 |
| Biomarkers: IBD (n = 132) vs. IBS (n = 22) | |||||||
| BGM | 0.70 (0.62–0.78) | <0.001 | 60 | 91 | 98 | 28 | 85† |
| EL-NE | 0.77 (0.69–0.83) | <0.001 | 78 | 65 | 93 | 34 | 85† |
| C5M | 0.56 (0.48–0.64) | NS | 62 | 57 | 89 | 21 | 85† |
| Pro-C5 | 0.71 (0.59–0.83) | <0.001 | 78 | 61 | 92 | 33 | 85† |
| VICM | 0.59 (0.51–0.66) | NS | 83 | 41 | 89 | 29 | 85† |
| CRP | 0.51 (0.43–0.59) | NS | 51 | 58 | 88 | 17 | 85† |
| EL-NE+BGM+Pro-C5* | 0.83 (0.76–0.88) | <0.001 | 68 | 91 | 98 | 32 | 85† |
| Biomarkers: IBD (n = 132) vs. healthy donors (n = 24) | |||||||
| BGM | 0.61 (0.53–0.69) | <0.01 | 46 | 79 | 92 | 21 | 85† |
| EL-NE | 0.65 (0.57–0.72) | <0.01 | 52 | 96 | 99 | 27 | 85† |
| C5M | 0.91 (0.85–0.95) | <0.001 | 84 | 92 | 98 | 51 | 85† |
| Pro-C5 | 0.93 (0.88–0.96) | <0.001 | 86 | 88 | 97 | 54 | 85† |
| C5M+Pro-C5+EL-NE* | 0.98 (0.95–0.99) | <0.001 | 86 | 88 | 97 | 54 | 85† |
| Biomarkers: IBS (n = 22) vs. healthy donors (n = 24) | |||||||
| BGM | 0.64 (0.49–0.78) | <0.05 | 91 | 58 | 67 | 88 | 64 |
| EL-NE | 0.75 (0.60–0.86) | NS | 68 | 96 | 83 | 75 | 76 |
| C5M | 0.92 (0.80–0.98) | <0.001 | 96 | 83 | 84 | 96 | 92 |
| Pro-C5 | 0.83 (0.69–0.92) | <0.001 | 96 | 63 | 70 | 94 | 83 |
| C5M+Pro-C5+EL-NE* | 0.96 (0.86–1.0) | <0.001 | 96 | 88 | 88 | 96 | 98 |
Abbreviations: AUC: Area under the curve, CI: Confidence interval, Sens: Sensitivity, Spec: Specificity, PPV: Positive predictive value, NPV: Negative predictive value, DA: Diagnostic accuracy
* Best logistic regression model with combination of biomarkers.
†sample size is too low for the control groups (IBS and healthy donors) resulting in overestimation of the diagnostic value.